Tesamorelin Lyophilized Powder

Overview

Tesamorelin (CAS 218949-48-5) is a 44-amino acid synthetic peptide analogue of endogenous growth hormone-releasing hormone (GHRH), with a trans-3-hexenoic acid moiety conjugated at the N-terminus to enhance stability against plasma dipeptidyl peptidase IV (DPP-IV) degradation — a key limitation of native GHRH in clinical applications. By binding and activating the GHRH receptor on pituitary somatotroph cells, tesamorelin stimulates pulsatile GH secretion, which in turn raises circulating IGF-1 levels and promotes visceral adipose tissue lipolysis. Tesamorelin received FDA approval in 2010 for HIV-associated lipodystrophy, making it one of the few research peptides with a complete Phase 3 clinical trial dataset and regulatory approval. Its well-characterized pharmacokinetic profile and established clinical dosing data make it a frequently sourced compound for researchers studying GH axis modulation, metabolic disorders, and body composition.

Technical Specifications

Key Research Findings

The pivotal Phase 3 clinical trial by Falutz et al., published in the New England Journal of Medicine in 2007, evaluated tesamorelin (2 mg/day subcutaneous) versus placebo in 412 HIV-infected patients with excess abdominal fat over 26 weeks [1]. Tesamorelin treatment produced a statistically significant reduction in visceral adipose tissue (VAT) of approximately 15% compared to placebo, alongside improvements in trunk-to-limb fat ratio and patient-reported body image outcomes — without adverse effects on glucose homeostasis at the doses tested. This trial formed the basis for FDA approval and remains the foundational dataset for tesamorelin’s clinical evidence base.

Beyond lipodystrophy, tesamorelin’s role in cognitive function research has attracted increasing attention. A randomized controlled trial by Baker et al. published in the Journal of the American Medical Association in 2012 investigated tesamorelin’s effect on cognition in older adults at risk for Alzheimer’s disease, finding significant improvements in executive function and verbal memory compared to placebo over 20 weeks — an effect associated with the compound’s IGF-1-elevating activity [2]. This expanded the research application profile beyond metabolic endpoints and positioned tesamorelin as a tool for investigators studying GH axis modulation in aging and neurological contexts.

Why Purity Matters

Tesamorelin’s N-terminal trans-3-hexenoic acid conjugation is the structural feature responsible for its DPP-IV resistance and extended half-life compared to native GHRH. This modification must be intact and correctly attached for the compound to achieve its characteristic pharmacokinetic profile. HPLC purity analysis confirms the percentage of the correctly synthesized principal component, while MS identity confirmation verifies that the molecular weight matches the full tesamorelin structure — including the N-terminal modification. Batches with incomplete conjugation or sequence errors will show variable GH stimulation in research models and cannot reliably replicate published clinical dosing outcomes. For researchers designing protocols based on published tesamorelin data, batch-level purity at ≥99% with MS confirmation is the minimum standard for reproducible results.

References:
[1] Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. N Engl J Med. 2007;357(23):2359–70. PMID: 18057340
[2] Baker LD, et al. Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with Mild Cognitive Impairment and Healthy Older Adults. Arch Neurol. 2012;69(11):1420–9. PMID: 22869065

Quality & Documentation

Each batch of tesamorelin lyophilized powder is individually tested before shipment. Included with every order:

• HPLC purity verification (≥99%)
• Mass spectrometry (MS) identity confirmation
• Batch number for full traceability

COA available upon request before order commitment.

Browse our full peptide catalog:

Lyophilized Peptide Powders

FAQ

Q: Is tesamorelin the same as native GHRH?
No. Tesamorelin (CAS 218949-48-5) is a synthetic analogue of human GHRH with a trans-3-hexenoic acid group at the N-terminus, which confers resistance to DPP-IV degradation and extends its half-life compared to native GHRH (CAS 9034-40-6). This structural difference is responsible for tesamorelin’s clinical utility and its distinct pharmacokinetic profile in published research.

Q: What is the difference between tesamorelin and sermorelin?
Both are synthetic GHRH analogues that stimulate pituitary GH secretion. Sermorelin (CAS 86168-78-7) is a 29-AA fragment of GHRH without N-terminal modification; tesamorelin is a 44-AA GHRH analogue with the trans-3-hexenoic acid conjugation for DPP-IV resistance. Tesamorelin has a longer half-life, a complete Phase 3 dataset, and FDA approval for HIV-associated lipodystrophy. Both are available from Vitaconin with individual COA documentation.

Q: How should tesamorelin be stored?
Store unreconstituted lyophilized tesamorelin at −20°C, sealed, away from light and moisture. Shelf life is 24 months under proper conditions. Once reconstituted, use within the timeframe specified in the COA and store at 2–8°C.